Incyte (INCY) Total Non-Current Liabilities (2013 - 2026)
Incyte (INCY) posted Total Non-Current Liabilities of $1.6 billion for Q1 2026, down 2.19% on a QoQ basis from $1.6 billion in Q4 2025, and down 16.61% year-over-year from $1.9 billion in Q1 2025.
Incyte (INCY) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Incyte's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $1.6 billion for Q1 2026.
- Quarterly Total Non-Current Liabilities fell 16.61% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 16.61% YoY) and the FY2025 annual result came in at $1.6 billion, down 11.15% from the prior year.
- Total Non-Current Liabilities was $1.6 billion for Q1 2026 at Incyte, down from $1.6 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.9 billion in Q1 2025 and bottomed at $987.0 million in Q1 2022.
- A 5-year average of $1.5 billion and a median of $1.5 billion in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 54.44% — and 2026, when it fell 16.61%.
- Incyte's Total Non-Current Liabilities stood at $1.3 billion in 2022, then gained by 12.18% to $1.4 billion in 2023, then increased by 26.75% to $1.8 billion in 2024, then dropped by 11.15% to $1.6 billion in 2025, then slipped by 2.19% to $1.6 billion in 2026.
- Business Quant data shows INCY's Total Non-Current Liabilities at $1.6 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 746.94 Mn |
| 10 | Incyte | 23.47 Bn | 19.46 Bn | 1.17 Bn | 1.59 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.59 Bn |
| Dec 31, 2025 | 1.63 Bn |
| Sep 30, 2025 | 1.51 Bn |
| Jun 30, 2025 | 1.47 Bn |
| Mar 31, 2025 | 1.91 Bn |
| Dec 31, 2024 | 1.83 Bn |
| Sep 30, 2024 | 1.67 Bn |
| Jun 30, 2024 | 1.52 Bn |
| Mar 31, 2024 | 1.59 Bn |
| Dec 31, 2023 | 1.44 Bn |
| Sep 30, 2023 | 1.32 Bn |
| Jun 30, 2023 | 1.33 Bn |
| Mar 31, 2023 | 1.22 Bn |
| Dec 31, 2022 | 1.29 Bn |
| Sep 30, 2022 | 1.21 Bn |
| Jun 30, 2022 | 1.16 Bn |
| Mar 31, 2022 | 987.02 Mn |
| Dec 31, 2021 | 1.09 Bn |
| Sep 30, 2021 | 987.87 Mn |
| Jun 30, 2021 | 749.75 Mn |